Peer-influenced content. Sources you trust. No registration required. This is HCN.

Journal of Clinical OncologyPhase 2 trial in oeso-gastric adenocarcinoma (OSA) showed pathologic complete response in 59% of patients. Data update expected at ASCO 2022.

Neo-adjuvant therapy with nivolumab and ipilimumab is associated with a high pCR rate in ptsd with MSI/dMMR resectable OGA.

The Healthcare Communications Network is owned and operated by IQVIA Inc.

Click below to leave this site and continue to IQVIA’s Privacy Choices form